Navigation Links
Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution
Date:4/25/2008

ia's largest pharmaceutical company. Ohm is engaged in the sale and distribution of generic and branded private label, OTC products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.

*Children's Zyrtec(R) Oral Solution is a registered trademark of McNeil Consumer Healthcare.

CONTACTS: Charles M. Caprariello

Vice President, Corporate Communications

Ranbaxy Inc.

(609) 720-5615

Edwige Buteau

RF Binder Partners Inc.

(212) 994-7517

Caroline Mozingo

RF Binder Partners Inc.

(212) 994-7560


'/>"/>
SOURCE Ranbaxy Laboratories Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension
2. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
3. Ranbaxy Receives Tentative Approval For Valsartan Tablets
4. Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP
5. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
6. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
7. Michael E. DeBakey Receives Congressional Gold Medal
8. Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum
9. Cadient Group Receives Multiple Awards at 2008 DTC National Advertising Awards
10. The National Exercise & Sports Trainers Association Receives Accreditation of Its Personal Fitness Trainer Certification From the National Commission for Certifying Agencies (NCCA)
11. PainCare Receives Notices From American Stock Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 The South American air ... million in 2014 and is expected to register a CAGR ... spends mainly on tackling internal security issues like drug trafficking. ... 75% share in the air and missile defense radar market. ... promising future in the market for radar systems in terms ...
(Date:7/24/2014)... The National Resident Matching Program (NRMP) ... new version of its smartphone app, The MATCH Program ... participating in NRMP’s Main Residency Match® and Specialties Matching ... program information during the interview process and develop program ... order lists. Rank order lists are used by ...
(Date:7/24/2014)... Indianapolis* VxP Pharma Services announced today ... include process development and commercial manufacturing for ... offered by VxP now include:, ...     Sterile Liquids and Sterile Powders , ...     Transdermal Patches ,     Animal Health ...
(Date:7/24/2014)... July 24, 2014 Becker's Hospital Review ... Hospitals and Health Systems With Great Oncology Programs." Organizations ... terms of quality patient care, cancer outcomes and research. ... for inclusion based on rankings and awards they have ... awards were considered as part of the criteria for ...
(Date:7/24/2014)... Dr. Kwame Bawuah Edusei, a diplomat, entrepreneur, medical ... to the youth to persevere in their endeavors to ... the youth to stay away from social vices and ... will afford you the opportunity of acquiring life surviving ... in your career path.” Professionals in the fields of ...
Breaking Medicine News(10 mins):Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 2Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 3Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 4Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 5Health News:National Resident Matching Program® (NRMP®) Releases New, Enhanced Version of its Smartphone App 2Health News:National Resident Matching Program® (NRMP®) Releases New, Enhanced Version of its Smartphone App 3Health News:VxP Pharma Expands Commercial Service Offering 2Health News:100 Hospitals, Health Systems With Great Oncology Programs 2Health News:100 Hospitals, Health Systems With Great Oncology Programs 3Health News:100 Hospitals, Health Systems With Great Oncology Programs 4Health News:Youth and Professionals Interact at Washington Metro Area Career Workshop Hosted by the Edusei Foundation 2
... Investigators at Hospital for Special Surgery, collaborating with researchers ... a gene called interferon regulator factor-8 (IRF-8) is involved ... disease), rheumatoid arthritis and osteoporosis. The study, which will ... the journal Nature Medicine , could lead to ...
... , , , ... Boehringer Ingelheim today announced that results from the RE-LY(R) (Randomized Evaluation ... largest atrial fibrillation (AF) outcomes trial ever conducted(1) (18,113 patients in ... the European Society of Cardiology Congress and published online in the ...
... , , WILMINGTON, Del., Aug. 30 ... the phase III head to head trial, PLATO (A Study of ... that ticagrelor (BRILINTA(TM)) has achieved greater efficacy in the primary endpoint, ... (9.8% vs. 11.7% at 12 months; 16% RRR; 95% CI, 0.77 ...
... watched by typical U.S. teens, analysis finds , FRIDAY, ... attract a significant proportion of teenage viewers are also ... research has found. , Using Nielsen Media Research advertising ... aired on cable TV from 2001 through 2006. The ...
... ... upheld to more stringent standards, including medical credentialing , with the influx of ... ... 29, 2009 -- According to an article from the Journal of General Internal Medicine, ...
... , ... national leader in deliciously healthy, ready to heat and eat meals, are applauding the ... weight loss is all about portion-controlled, properly balanced meals. , ... Lorton, VA (PRWEB) August 29, 2009 -- Officials at Diet-to-Go, ...
Cached Medicine News:Health News:Researchers identify protein involved in causing gum disease, osteoporosis, arthritis 2Health News:Researchers identify protein involved in causing gum disease, osteoporosis, arthritis 3Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 2Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 3Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 4Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 5Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 6Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 7Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 8Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 9Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 2Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 3Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 4Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 5Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 6Health News:Alcohol Ads on Cable TV Reach Young Audiences 2Health News:Alcohol Ads on Cable TV Reach Young Audiences 3Health News:Foreign Physician Growth in the U.S. and the Impact on Medical Credentialing 2Health News:Foreign Physician Growth in the U.S. and the Impact on Medical Credentialing 3Health News:Diet-to-Go Asks: Isn't it TIME You Listened to the Facts About Weight Loss? 2Health News:Diet-to-Go Asks: Isn't it TIME You Listened to the Facts About Weight Loss? 3
(Date:7/24/2014)... July 24, 2014 Cancer patients in the west ... state-of-the-art cancer treatment closer to home when a new radiotherapy ... Varian Medical Systems (NYSE: VAR ) has been ... placed in June for four TrueBeam™ medical linear accelerators. ... fast and efficient radiotherapy and radiosurgery treatments, will replace older ...
(Date:7/24/2014)... Second Quarter and Recent Highlights: , Appointed Pat ... 2, 2014 , Product revenues grew 12 percent ... revenues grew 14 percent year-over-year to $15.3 million ... to $1.1 million , HeRO ® Graft ... , Tissue processing revenues decreased 6 percent year-over-year to ...
(Date:7/24/2014)... Quebec , July 24, 2014 ... VRX ) (TSX:VRX) announced today that it has ... marches financiers ("AMF") regarding Allergan, Inc.,s (NYSE: ... and to negatively influence the market price of ... and misleading statements regarding Valeant,s business despite Valeant,s ...
Breaking Medicine Technology:Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 2CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 3CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 4CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 5CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 6CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 7CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 8CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 9CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 10CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 11CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 12CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 13CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 14CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 15CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 16CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 17Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 2Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 3Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 4Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 5Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 6
... , GUANGZHOU, China, Nov. ... ("China Medicine" or "the Company"), a developer,and a leading ... nutritional and dietary supplements, and,medical devices and medical formulations, ... Third Quarter 2009 Highlights:, ...
... LAIYANG, China, Nov. 16 /PRNewswire-Asia-FirstCall/ -- Jiangbo,Pharmaceuticals, ... pharmaceutical company with its principal operations in the People,s,Republic of ... at 9:00 a.m. Eastern Time on Wednesday, November 18, 2009 ... 2010. , Conference Call , ...
Cached Medicine Technology:China Medicine Announces Strong Third Quarter 2009 Results 2China Medicine Announces Strong Third Quarter 2009 Results 3China Medicine Announces Strong Third Quarter 2009 Results 4China Medicine Announces Strong Third Quarter 2009 Results 5China Medicine Announces Strong Third Quarter 2009 Results 6China Medicine Announces Strong Third Quarter 2009 Results 7China Medicine Announces Strong Third Quarter 2009 Results 8China Medicine Announces Strong Third Quarter 2009 Results 9China Medicine Announces Strong Third Quarter 2009 Results 10China Medicine Announces Strong Third Quarter 2009 Results 11China Medicine Announces Strong Third Quarter 2009 Results 12China Medicine Announces Strong Third Quarter 2009 Results 13China Medicine Announces Strong Third Quarter 2009 Results 14China Medicine Announces Strong Third Quarter 2009 Results 15Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010 2
Full Handle Laseredge Implant Blade Knife, 5.2 mm angled bevel up. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Implant Blade Knife, 4.0 mm angled bevel up. Blade dimension: 15.2 mm x 4.0 mm x 3.0 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel down. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, straight. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Medicine Products: